Avalo Therapeutics Inc. Common Stock AVTX · Stock Open Avalo Therapeutics Inc. Common Stock in new tab
Avalo Therapeutics Inc. Common Stock Analysis (AVTX)
Is Avalo Therapeutics Inc. Common Stock a good investment? Avalo Therapeutics Inc. Common Stock (AVTX) is currently trading at 18.84 USD. Market analysts have a consensus price target of 45.25 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 2.30. This relatively low multiple may signal that Avalo Therapeutics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Avalo Therapeutics Inc. Common Stock is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -2.80.
Investor FAQ
Does Avalo Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Avalo Therapeutics Inc. Common Stock?
Avalo Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -5.57.
Company Profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 29, 2023 | 0.000000 |
| July 8, 2022 | 0.080000 |
Community Discussion